# Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

> **NCT05442710** · PHASE2 · RECRUITING · sponsor: **Artcline GmbH** · enrollment: 142 (estimated)

## Conditions studied

- Sepsis, Severe

## Interventions

- **BIOLOGICAL:** ARTICE

## Key facts

- **NCT ID:** NCT05442710
- **Lead sponsor:** Artcline GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-24
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442710, "Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05442710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*